Mean platelet volume in acute pancreatitis: a systematic review and meta-analysis

Vasileios P. Papadopoulos^{a,b}, Dimitrios K. Filippou^c, Konstantinos P. Mimidis^b

ENARGEIA Medical Ltd., Xanthi; Democritus University of Thrace, Thrace, Alexandroupolis; National and Kapodistrian University of Athens, Greece

Abstract

Background Several studies have suggested there may be statistically significant differences in mean platelet volume (MPV) between the onset and remission of acute pancreatitis (AP). This systematic review and meta-analysis aimed to better characterize the correlation between MPV and AP by identifying all relevant studies and summarizing their results.

Methods A comprehensive literature review was conducted using EMBASE, PubMed/MEDLINE, Cochrane Library, ClinicalTrials.gov, and Google Scholar from January 2000 to December 2019 to identify all studies that reported MPV at the onset or remission of AP, or both. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird. The Newcastle-Ottawa quality assessment scale was used to appraise the quality of the included studies.

Results Ten observational studies, including 1019 patients and 363 controls, were included in the meta-analysis. MPV was smaller at the onset of AP than on remission (standardized mean difference= -0.33 fL, 95% confidence interval -0.54 to -0.12 fL; P=0.002); however, a moderate degree of heterogeneity (I^2 =72%, P≤0.001) was observed. Subgroup analysis indicated comparable MPV in relation to the severity of AP. Similarly, no statistically significant difference was detected between AP patients and controls at either onset (P=0.760) or remission (P=0.700) of the disease. No statistically significant publication bias was detected (Eggers' regression P=0.938). Subgroup analysis suggested age (P<0.001) and sex (P=0.01) adjustment as potential sources of heterogeneity.

Conclusion MPV is smaller at the onset of AP. Further clinical evaluation is needed to assess its potential prognostic value.

Keywords Pancreatitis, mean platelet volume, blood platelets

Ann Gastroenterol 2020; 33 (4): 398-404

Introduction

It has been claimed that platelets are directly involved in the pathophysiology of acute pancreatitis (AP) [1]. An elevated

^aDepartment of Internal Medicine, ENARGEIA Medical Ltd., Xanthi (Vasileios P. Papadopoulos); ^bFirst Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis (Vasileios P. Papadopoulos, Konstantinos P. Mimidis); ^cLaboratory of Anatomy, Medical School, National and Kapodistrian University of Athens (Dimitrios K. Filippou), Greece.

Conflict of Interest: None

Correspondence to: Vasileios P. Papadopoulos, 6 Elpidos St., 67131 Xanthi, Greece, e-mail: vaspapmd@gmail.com

Received 28 January 2020; accepted 7 April 2020; published online 15 May 2020

DOI: https://doi.org/10.20524/aog.2020.0495

© 2020 Hellenic Society of Gastroenterology

activated platelet ratio has been observed at the onset of AP [2]. Moreover, greater platelet adhesiveness and aggregation has been documented in the early stages of the disease [3]. Mean platelet volume (MPV) has been proposed as a marker of platelet consumption and resulting compensatory bone marrow response during the disease process [2].

Several studies have reported statistically significant differences in MPV between the onset and remission of AP; furthermore, elevated MPV at admission has been linked with persistent organ failure in these patients [4]. However, the related literature remains obscure and thus needs further consolidation and clarification. Moreover, as properly designed prospective cohorts are still lacking, the potential prognostic value of MPV during the course of AP has so far remained elusive.

The present systematic review and meta-analysis was conducted with the aim of providing further evidence regarding a potential correlation between MPV and AP by identifying all relevant studies and summarizing their results.

Materials and methods

A systematic literature review was conducted using EMBASE, PubMed/MEDLINE, Cochrane Library, and ClinicalTrials.gov databases from January 2000 to December 2019 to identify all studies that reported MPV at the onset or remission of AP, or both. The Google Scholar database was used as an additional pool of published data; an iterative search was performed until no additional publications could be traced. Lastly, we searched for unpublished dissertations and other unpublished work. The relevant protocol was submitted to the PROSPERO database (ID: 150901).

The review was independently conducted by 2 authors (VP and DF) using a search strategy that included the terms "mean platelet volume", "MPV" and "pancreatitis"; a third author (KM) was responsible for resolving any discordance. No software was used for study retrieval. Sources of financial support were traced where possible. The present study was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines to formulate the basis of pre-specified eligibility criteria using the PICO (P-Populations/People/Patient/Problem: Patients in acute phase of AP and controls, I-Intervention(s): AP, C-Comparison: between patients at onset and remission (at discharge or at least 7 days after admission) of AP; between patients at onset of AP and controls; between patients at remission of AP and controls; between severe and mild cases at onset of AP, O-Outcome: MPV) worksheet and search strategy [5]. The AMSTAR checklist was used to confirm the high quality of the present meta-analysis [6].

Eligible studies were all that: 1) were written in English; 2) were case-control studies; 3) had a consistent outcome of interest; 4) reported a measure of statistical significance; 5) reported an effect size (means accompanied by their standard deviations); and 6) reported effect estimates not already reported.

The Newcastle-Ottawa quality assessment scale (NOS) was used to appraise the quality of the included studies in 3 areas: namely, the identification and recruitment of participants, the comparability between the 2 groups and the ascertainment of the exposure of interest [7]. Kappa statistics were used for the evaluation of inter-rater agreement in the case of NOS.

A structured data collection form was used to extract the following data from each study: title of the study, name of the first author, year of publication, country where the study was conducted, number of patients, severity of cases (if reported), number of controls (if any), correlation coefficient between paired data (if known), MPV of patients at onset of AP, MPV of patients at remission of AP, MPV of controls and adjustment for potential confounders (sex, age and body mass index). The data extraction process was carried out by 2 authors (VP and DF); a third author (KM) was responsible for cross-checking in case of any discordance.

Data analysis was performed using Revman 5.3 software from the Cochrane Collaboration (London, United Kingdom). As effect estimates, standardized mean differences (SMD) and confidence intervals (CI) expressed in fL were utilized. Effect estimates from each study were combined together using the random-effect, generic inverse variance method of DerSimonian and Laird, which assigned the weight of each study in the pooled analysis inversely to its variance [8]. In cases that median and interquartile range (IQR) were available, mean was considered equal to median and standard deviation (SD) was approached by the formula IQR/1.35 if normal distribution was reported; otherwise, the.xls tool based on the approach of Wan *et al* was applied [9].

As data between onset and remission of AP are paired, pooled SD was used, as approached by the formula $[SD_{onset}^2 + SD_{remis}^2]$ - 2 × r × SD_{onset} × SD_{remis}]^{1/2}, where SD_{onset}, SD_{remis} and r denote SD at onset of AP, SD at remission of AP and the correlation coefficient between data. In cases where r was unknown, it was arbitrarily given a value of 0.5 if statistical significance was reported; otherwise, the r value was nullified. Analysis of publication bias was performed through Eggers' regression, funnel plot with trim-and-fill analysis, standardized residual histogram, Galbraith plot, normal quintile plot, Rosenthal failsafe-N test, Orwin failsafe-N test and Gleser & Olkin number of unpublished studies with the aid of Meta-Essentials software [10]. Analysis of heterogeneity, as derived from the Q test and I^2 statistic (Q test P-value <0.10 was indicative of a statistically significant result; furthermore, a value of $I^2 \le 25\%$ was indicative of insignificant heterogeneity, 26-50% of low heterogeneity, 51-75% of moderate heterogeneity and >75% of high heterogeneity), was performed through meta-regressions focusing on study characteristics, biases and confounders; multivariate analysis as well as subgroup analysis followed in case of univariate P<0.1 [11]. All statistical tests were carried out using SPSS 20.0 software (IBM Corp ©).

Results

Forty-nine potentially relevant publications were identified through a thorough search of the literature; 15 were retrieved from EMBASE, 13 from PubMed/MEDLINE, 4 from ClinicalTrials.gov, and 17 from Google Scholar databases. No relevant publication was recognized in the Cochrane Library. No unpublished data of interest were detected.

After the exclusion of 31 duplicates, all the remaining 18 publications were initially reviewed based only on title and abstract; 5 failed to fulfill the eligibility criteria based on language, type of article, study design, and measured outcomes. The remaining 13 publications were reviewed based on full text; 3 were excluded from the meta-analysis (1 letter and 2 reporting irrelevant outcomes). Finally, 10 case-control studies with 1019 patients and 363 controls were included in the meta-analysis (Fig. 1).

All the characteristics of the studies and their quality assessment are presented in Table 1. The inter-rater agreement for NOS was high (kappa=0.78). The relevant data did not reveal any profound quality handicap.

The pooled analysis demonstrated that MPV was lower at the onset of AP than at remission of the disease (SMD=-0.33 fL, 95%CI -0.54 to -0.12 fL; P=0.002); however,




Figure 1 Flow chart

moderate heterogeneity (I²=72%, P<0.001) was observed. Subgroup analysis indicated comparable MPV in relation to the severity of AP (SMD=-0.42 fL, 95%CI -1.02 to 0.17; P=0.170). Similarly, no statistically significant difference was detected between AP patients and controls at either onset (SMD=0.12 fL, 95%CI -0.61 to 0.84 fL; P=0.760) or remission (SMD=0.07 fL, 95%CI -0.31 to 0.46 fL; P=0.700) of the disease (Fig. 2). No statistically significant publication bias was detected (Eggers' regression P=0.938). Furthermore, the Rosenthal failsafe-N test rejected the ad-hoc rule (Failsafe-N=206), Orwin failsafe-N was null and Gleser & Olkin number of unpublished studies was 13, fairly close to the number of studies included in the present meta-analysis. Moreover, the funnel plot was not indicative of lack of symmetry and trim-and-fill analysis produced no imputed data points (Fig. 3). The Galbraith plot is depicted in Supplementary Fig. 1.

No statistically significant model analyzing study characteristics and potential confounders explained heterogeneity by meta-regression (Table 2). However, subgroup analysis suggested age (P<0.001) and sex (P=0.010) adjustment as potential sources of heterogeneity (Table 3).

Discussion

The question of whether platelets are directly involved in the pathophysiology of AP has remained controversial since it was first proposed in 2 studies of ours: the former concluded that an elevated activated platelet ratio has been observed at the onset of AP [2] and the latter that platelet adhesiveness and aggregation are greater in the early stages of the disease [3]. Furthermore, our team proposed that MPV could reflect platelet consumption and resulting compensatory bone marrow response during AP, thus being a potential candidate marker for the disease process, whose clinical usefulness remains to be tested [2]. Since then, several studies have been carried out in this area.

Three studies are in keeping with our results, having reported statistically significant differences in MPV between onset and remission of AP [13,18,19]. In 2 of them, the result was independent of the severity of the disease [18,19]. Interestingly, Beyazit et al [13] discriminated between mild and severe AP, concluding that MPV has a crucial value in determining disease severity; furthermore, comparisons of MPV with other inflammatory markers, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (WBC) reported better overall accuracy for the former (72.7% at a cutoff of 7.85 fL). In keeping with the above mentioned results, Erbis et al proposed a very similar cutoff (7.80 fL) to discriminate between necrotizing and non-necrotizing AP [17]. Additionally, a cutoff of 12 fL was used as a prognostic indicator of persistent organ failure in patients with AP in the work carried out by Huang et al [4].

In contrast, Osada et al reported comparable MPV values between the onset and remission of AP [14]. This study underlines that platelets, which provide the cellular link between the inflammatory response and the activation of coagulation, may play an important role in the initiation of AP and the development of serious complications. The authors evaluated platelet morphology along with functional parameters in relation to the severity of AP, and concluded that patients with severe AP presented significantly lower MPV than controls at disease onset. Furthermore, they stated that patients with AP, independently of disease severity, exhibited an increase in high volume platelets at remission of the disease and proposed that this phenomenon could be explained in terms of reactive thrombocythemia. In keeping with the latter, Kefeli et al reported a significantly increased platelet count at remission of AP in comparison with the onset of disease; however, the authors reported comparable MPV at onset and remission of AP, as well as in controls [16]. Yarkaç et al also reported comparable MPV values between the onset and remission of AP and their best cutoff value for MPV to discriminate mild from severe cases of AP (9.4 fL) failed to reach statistical significance (P=0.067) [20].

Akbal *et al* reported a greater MPV at the onset of AP when compared with controls; however, they found comparable MPV values between the onset and remission of AP. Furthermore, the authors reported that MCV was correlated with D-dimers and fibrinogen levels but not with inflammation markers (CRP, ESR, and WBC) proposing that higher MPV levels in acute pancreatitis may reflect hypercoagulation associated with the disease [15].

As far as the etiology of AP is concerned, Okuturlar *et al* reported lower MPV in patients with non-biliary AP compared with biliary AP at both onset and remission of the disease,

Study	Region	Endpoint	Patients	Controls	ц	MPV (Onset)	MPV (Remission)	MPV (Controls)	Adjusted confounders	NOS selection	NOS comparability	NOS exposure
Mimidis, 2004 [2]	Greece	Onset vs. Remission	52	1	0.79	9.6±1.2	10.3 ± 1.2		Sex, age	ななな	자자	나라라
Yilmaz, 2011 [12]	Turkey	Onset vs. Controls	30	30		$8.8{\pm}1.3$	ı	7.9±0.5	Sex, age, BMI	삼석	4	ななな
Beyazit, 2012 [13]	Turkey	Onset vs. Remission vs.	144	40		$8.1 {\pm} 0.7$	ı	$8.6 {\pm} 0.6$	Sex, age	ななな	각각	나라라
		Controls	Mild 93		0.50	8.3±0.7	8.5±0.8					
			Severe 51		0.50	7.7±0.6	8.2 ± 1.0					
Osada, 2012 [14]	Poland	Onset vs. Remission vs.	40	25		,	ı	$8.9{\pm}0.8$	1	ななな	각각	삼삼삼
		Controls	Mild16		0.00	9.5±0.8	9.2±1.1					
			Severe 24		0.00	9.6±1.0	9.5±1.1					
Akbal, 2013 [15]	Turkey	Onset vs. Remission vs. Controls	24	24	0.00	8.6±1.4	8.5±1.2	7.6±0.7	Sex, age	각각각	なな	ななな
Kefeli, 2014 [16]	Turkey	Onset vs. Remission vs. Controls	140	70	0.00	7.8±1.6	7.7±0.9	7.8±1.1	Age	남 남 남 남	なな	ななな
Erbis, 2015 [17]	Turkey	Onset vs. Controls	76 Mild 40 Severe 36	40		7.5±0.6 7.9±0.5 7.2±0.5	1	8.3±0.9	Age	**	**	**
Okuturlar, 2015 [18]	Turkey	Onset vs. Remission vs. Controls	332 Biliary 195 Non-biliary 137		0.50	8.4 ± 1.0 8.1 ± 1.0	8.7 ± 1.1 8.4 ± 1.0	8.3±0.9	Age	***	**	***
Lei, 2017 [19]	China	Onset vs. Remission vs.	117	34		8.7±2.4	10.4 ± 1.7	11.0 ± 1.4	Sex, age	ななな	なな	ななな
		Controls	Mild 78		0.50	8.9±2.3	9.7±1.8					
			Severe 39		0.50	8.5±2.5	10.5 ± 1.8					
Yakac, 2019 [20]	Turkey	Onset vs. Controls	168 Mild 122 Severe 46	100		9.5 ± 1.3 9.5 ± 1.2 9.8 ± 1.3		8.0±0.7	Sex, age	~~~~~	**	ななな
MPV, mean platelet voi	lume; NOS,	MPV, mean platelet volume; NOS, Newcastle-Ottawa scale; BMI, body mass index	ly mass index									

 Table 1 Eligible studies (characteristics and quality assessment)

Annals of Gastroenterology **33**

	C	Inset		Re	emissio	1		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SI	<u>Total</u>	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Mimidis, 2004	9.6	1.2304	54	10.3	1.2304	54	10.2%	-0.56 [-0.95, -0.18]	2004	[
Osada, 2012 (severe)	9.6	1.4866	24	9.5	1.486		7.3%	0.07 [-0.50, 0.63]	2012	
Osada, 2012 (mild)	9.5	1.3601	16		1.360		5.7%	0.22 [-0.48, 0.91]	2012	
Beyazit, 2012 (severe)	7.66	0.8927	51		0.892		10.0%	-0.63 [-1.03, -0.24]	2012	
Beyazit, 2012 (mild)	8.27	0.7671	93		0.767		12.0%	-0.25 [-0.54, 0.04]	2012	
Akbal, 2013	8.6	1.8439	24		1.843		7.3%	0.05 [-0.51, 0.62]	2013	
Kefali, 2014	7.8	1.8358	140		1.835		13.1%	0.05 [-0.18, 0.29]	2013	
	8.2756	1.0759	332		1.075			-0.28 [-0.44, -0.13]	2014	
Lei, 2017 (mild)		2.0547	78		2.054		11.3%	-0.75 [-1.08, -0.43]		
Lei, 2017 (severe)	0.47	2.2267	39	10.52	2.226	39	8.8%	-0.91 [-1.38, -0.44]	2017	
Total (95% CI)			851			851	100.0%	-0.33 [-0.54, -0.12]		•
Heterogeneity: Tau ² = 0.07	; Chi ² = 3	32.65, df	= 9 (P =	= 0.0002); l ² = 72	%				
Test for overall effect: Z = 3	3.09 (P =	0.002)			,.					-2 -1 0 1 2
										Onset Remission
		Patient			Control			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mea		D Tot			Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Yilmaz, 2011 (vs controls)	8.8	2 1.3	3 3	0 7.9	4 0.54	30	12.2%	0.86 [0.33, 1.39]	2011	
Osada, 2012 (vs controls)	9.5	6 0.915	6 4	0 8.	9 0.8	25	12.3%	0.75 [0.23, 1.26]	2012	
Beyazit, 2012 (vs controls)	8.05	4 0.711	8 14	4 8.6	3 0.62	40	12.7%		2012	
Akbal, 2013 (vs controls)	8.	6 1	.4 2	4 7.	6 0.7	24	12.0%		2013	
kefeli, 2014 (vs controls)	7.	8 1	.6 14	0 7.	8 1.1	70	12.8%		2014	
Erbis, 2015 (vs controls)	7.			6 8.		40	12.6%		2015	
						34	12.6%		2017	
Lei 2017 (vs.controls)	87				• • • •					
Lei, 2017 (vs controls) Yarkac, 2019 (vs controls)	8.7 9.5		25 16	8	8 0.74	100	12.8%	1.40 [1.13, 1.68]	2019	
, , ,			25 16	8	8 0.74	100	12.8%	1.40 [1.13, 1.68]	2019	
, , ,			25 16 73		8 0.74		12.8% 100.0%	1.40 [1.13, 1.68] 0.12 [-0.61, 0.84]	2019	-
Yarkac, 2019 (vs controls) Total (95% Cl)	9.5	3 1.2	73	9		363			2019	
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05	9.5 ; Chi ² = 1	3 1.2 194.24, d	73	9		363			2019	
Yarkac, 2019 (vs controls) Total (95% Cl)	9.5 ; Chi ² = 1	3 1.2 194.24, d	73	9		363			2019	-2 -1 0 1 Patients Controls
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05	9.5 ; Chi ² = 1	3 1.2 194.24, d	73 If = 7 (P	9		363 96%	100.0%		2019	-2 -1 0 1 2 Patients Controls Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05	9.5 ; Chi ² = 1	3 1.2 194.24, d 0.76) Patien	73 If = 7 (P	9 < 0.000	01); I ² = Contro	363 96%	100.0%	0.12 [-0.61, 0.84]		
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = (9.5 ; Chi ² = - 0.31 (P = Me	3 1.2 194.24, d 0.76) Patien an	73 If = 7 (P ts SD To	9 < 0.000 tal Me	01); I ² = Contro	363 96% Is) Tota	100.0%	0.12 [-0.61, 0.84] Std. Mean Difference		Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = (Study or Subgroup	9.5 ; Chi ² = - 0.31 (P = Me	3 1.2 194.24, d 0.76) Patien an 35 0.90	73 If = 7 (F ts <u>SD To</u> 32 1	9 < 0.000 tal Me 44 8.1	01); l² = Contro an SI	363 96% Is <u>5</u> Total 2 40	100.0% Weight	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% Cl -0.29 [-0.65, 0.06]	Year	Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Osada, 2012 (vs controls)	9.5 ; Chi ² = -).31 (P = <u>Me</u> 8.378 9.3	3 1.2 194.24, d 0.76) Patien an 35 0.90 38 1.0	73 If = 7 (P ts SD To 32 1 96	9 < 0.000 tal Me 44 8.1 40 8	01); I ² = Contro an SI 53 0.62	363 96% Is 2 40 3 25	100.0% Weight 21.7% 18.1%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98]	Year 2012	Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls)	9.5 ; Chi ² = - 0.31 (P = <u>Me</u> 8.378 9.3	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5	73 If = 7 (F 5D To 32 1 96	tal Me 44 8.4 40 8 24 7	01); I ² = Contro an SI 53 0.62 .9 0.4	363 96% 1s 7 Tota 2 40 3 25 7 24	100.0% Weight 21.7% 18.1% 16.2%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50]	Year 2012 2012	Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Osada, 2012 (vs controls) kefeli, 2014 (vs controls)	9.5 ; Chi ² = - 0.31 (P = <u>Me</u> 8.378 9.3	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5 .7	73 If = 7 (P ts SD To 32 1 96 1.2 0.9 1	19 tal Me 44 8.1 40 8 24 7	Contro an SI 53 0.62 .9 0.4 .6 0.7 .8 1.7	363 96% Tota 2 40 3 25 7 24 7 70	100.0% Weight 21.7% 18.1%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% Cl -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18]	Year 2012 2012 2013	Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls)	9.5 ; Chi ² = - 0.31 (P = <u>Me</u> 8.376 9.3 8 7	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5 .7	73 ff = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1	9 < 0.000 tal Me 44 8.1 40 8 24 7 40 7 17 10.1	Contro an SI 53 0.62 .9 0.4 .6 0.7 .8 1.7	363 96% Tota 2 40 3 25 7 24 1 70 4 34	Weight 21.7% 18.1% 16.2% 23.1% 21.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05]	Year 2012 2012 2013 2014	Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Osada, 2012 (vs controls) Akbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI)	9.5 ; Chi ² = - 0.31 (P = 8.37(9.3 8 7 10.4	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5 .7 .7 44 1.65	73 ff = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1 4	9 tal Me 44 8. 40 8 24 7 17 10. 65	Contro an SI 3 0.62 .9 0.1 .6 0. .8 1. 98 1.4	363 96% 0 Total 2 40 3 25 7 24 1 70 4 34 193	100.0% Weight 21.7% 18.1% 16.2% 23.1%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% Cl -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18]	Year 2012 2012 2013 2014	Std. Mean Difference
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Osada, 2012 (vs controls) Atbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14	9.5 ; Chi ² = - 0.31 (P = <u>Me</u> 8.37(9.(8.37(9.(10.4) ; Chi ² = -	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5 .7 14 1.65 18.04, df	73 ff = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1 4	9 tal Me 44 8. 40 8 24 7 17 10. 65	Contro an SI 3 0.62 .9 0.1 .6 0.7 .8 1.7 .98 1.4	363 96% 0 Total 2 40 3 25 7 24 1 70 4 34 193	Weight 21.7% 18.1% 16.2% 23.1% 21.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05]	Year 2012 2012 2013 2014	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Osada, 2012 (vs controls) Akbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI)	9.5 ; Chi ² = - 0.31 (P = <u>Me</u> 8.37(9.(8.37(9.(10.4) ; Chi ² = -	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5 .7 14 1.65 18.04, df	73 ff = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1 4	9 tal Me 44 8. 40 8 24 7 17 10. 65	Contro an SI 3 0.62 .9 0.1 .6 0.7 .8 1.7 .98 1.4	363 96% 0 Total 2 40 3 25 7 24 1 70 4 34 193	Weight 21.7% 18.1% 16.2% 23.1% 21.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05]	Year 2012 2012 2013 2014	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Osada, 2012 (vs controls) Atbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14	9.5 ; Chi ² = - 0.31 (P = <u>Me</u> 8.37(9.(8.37(9.(10.4) ; Chi ² = -	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 .5 .7 14 1.65 18.04, df 0.70)	73 If = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1 4 = 4 (P =	9 tal Me 44 8. 40 8 24 7 40 7 17 10. 65 = 0.001);	01); $I^2 =$ Contro an SI 33 0.6; .9 0.4; .6 0.7; .8 1.7; .8	363 96% 0 Total 2 40 3 25 7 24 1 70 4 34 193	100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46]	Year 2012 2012 2013 2014	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Akbal, 2014 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 0	9.5 ; Chi ² = - 0.31 (P = 	3 1.2 194.24, c 0.76) Patien an 5 0.90 38 1.0 5 1.2 18.04, df 0.70) Severe	73 ff = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1 4 = 4 (P =	9 tal Me 44 8.1 44 8.1 44 7 40 7 17 10.1 65 = 0.001);	01); I ² = Contro an Si 33 0.6; .9 0.4; 6 0.7; 8 1.7; 98 1.4; 1 ² = 78 ⁴ Mild	363 96% 7 Total 2 40 3 25 7 244 7 70 4 34 193 6	100.0% Weight 21.7% 18.1% 16.2% 23.1% 23.1% 21.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% Cl -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference	Year 2012 2012 2013 2014	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup	9.5 ; Chi ² = - 0.31 (P =	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 5 0.90 38 1.0 5 1.2 18.04, df 0.70) Severe n S	73 ff = 7 (P 5D To 32 1 96 1.2 0.9 1 61 1 4 = 4 (P =	9 tal Me 44 8.4 40 8 24 7 40 7 17 10.4 65 = 0.001); al Mea	01); ² = Contro an SI 53 0.6; .9 0.4; .6 0.7; .8 1.7; 98 1.4; ² = 78 ⁶ Mild an SD	363 96% 7 Total 2 40 3 25 7 24 1 70 4 34 193 6 Total	100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0% Weight	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI	Year 2012 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls)	9.5 ; Chi ² = - 0.31 (P =	3 1.2 194.24, d 0.76) Patien 3 an 3 35 0.90 36 1.0 .5 0.90 34 1.65 18.04, df 0.70) Severe n 2 7.7 0.6	73 15 15 16 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17	9 tal Me 44 8. 40 8 24 7 40 7 17 10. 65 = 0.001); al Mea 1 8.3	01); $ ^2 =$ Controp an SI 53 0.63; .9 0.3; .6 0.7; .8 1.7; .8 1.7;	363 96% 0 Total 2 40 3 25 7 24 7 34 193 6 Total 93	100.0% Weight 21.7% 18.1% 23.1% 21.0% 100.0% Weight 20.9%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54]	Year 2012 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup	9.5 ; Chi ² = - 0.31 (P =	3 1.2 194.24, c 0.76) Patien an 35 0.90 38 1.0 5 0.90 38 1.0 5 1.2 18.04, df 0.70) Severe n S	73 15 15 16 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17	9 tal Me 44 8. 40 8 24 7 40 7 17 10. 65 = 0.001); al Mea 1 8.3	01); $ ^2 =$ Controp an SI 53 0.63; .9 0.3; .6 0.7; .8 1.7; .8 1.7;	363 96% 7 Total 2 40 3 25 7 24 1 70 4 34 193 6 Total	100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0% Weight	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI	Year 2012 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) kefeli, 2014 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls)	9.5 ; Chi ² = - 0.31 (P =	3 1.2 194.24, d 0.76) Patien 3 an 3 35 0.90 36 1.0 .5 0.90 34 1.65 18.04, df 0.70) Severe n 2 7.7 0.6	73 50 7 7 7 7 7 7 7 7	9 tal Mee 44 8. 40 8 24 7 17 10. 65 = 0.001); al Mee 1 8.5 5 7.5	$\begin{array}{c} \text{O1}; \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	363 96% 0 Total 2 40 3 25 7 24 7 34 193 6 Total 93	100.0% Weight 21.7% 18.1% 23.1% 21.0% 100.0% Weight 20.9%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54]	Year 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Erbis, 2015 (vs controls) Lei, 2017 (vs controls)	9.5 ; Chi ² = - 0.31 (P =	3 1.2 194.24, d 0.76) Patien 35 35 0.90 38 1.0 .5 .7 .44 1.65 18.04, df 0.70) Severe g n 5 7.7 0.6 7.7 0.6 7.7 0.6 8.5 2.5	73 75 7 7 7 7 7 7 7 7 7 7	9 tal Me 44 8.1 40 8 40 7 717 10.1 65 = al Mea 1 8.3 5 7.3 5 8.3 6 8.3	$\begin{array}{c} \text{Controc}\\ \text{an} & \text{SI}\\ \hline 33 & 0.6;\\ .9 & 0.i,\\ .6 & 0.0;\\ .8 & 1.i \\ \hline 38 & 1.i \\ 1^2 = 78^i \\ \hline \text{Mild} & \text{SD}\\ \hline \text{m} & \text{SD}\\ \hline 3 & 0.7 \\ .9 & 0.5 \\ .9 & 2.3 \end{array}$	363 96% 1 Total 2 40 3 25 2 40 3 25 2 40 7 04 3 40 78	100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0% Weight 20.9% 19.4% 20.6%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54] -1.39 [-1.89, -0.88] -0.17 [-0.55, 0.22]	Year 2012 2012 2013 2014 2014	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Erbis, 2015 (vs controls) Erbis, 2015 (vs controls) Osada, 2012 (vs controls) Osada, 2012 (vs controls)	9.5 ; Chi ² = - 0.31 (P = 	3 1.2 194.24, c 0.76) Patien 35 35 0.90 38 1.00 .5 1.00 .6 1.00 .7 0.10 18.04, df 0.70) Severe n 5 7.7 0.6 7.7 0.5 9.6 1	73 5D To 5D To 32 1 12 332 1 132 1332 1 14 4 4 5 5 5 5 1 6 1 1 1 1 1 1 1 1	9 tal Me 44 8.1 40 8 40 7 7 10.1 65 = 1 8.3 5 7.5 9 8.63 9 8.63 4 9.4	Mild SI 1/2 - </td <td>363 96% 15 2 40 3 25 2 40 3 25 4 70 3 25 4 70 3 25 5 24 1 93 3 40 5 24 1 93 5 40 1 93 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9</td> <td>100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0% Weight 20.9% 19.4% 20.6% 18.0%</td> <td>0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54 -1.39 [-1.89, -0.88 -0.17 [-0.55, 0.22 0.11 [-0.53, 0.74]</td> <td>Year 2012 2013 2014 2017</td> <td>Std. Mean Difference IV, Random, 95% CI</td>	363 96% 15 2 40 3 25 2 40 3 25 4 70 3 25 4 70 3 25 5 24 1 93 3 40 5 24 1 93 5 40 1 93 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0% Weight 20.9% 19.4% 20.6% 18.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54 -1.39 [-1.89, -0.88 -0.17 [-0.55, 0.22 0.11 [-0.53, 0.74]	Year 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Erbis, 2015 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Akbal, 2012 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Cosada, 2012 (vs controls) Yarkac, 2019 (vs controls)	9.5 ; Chi ² = - 0.31 (P = 	3 1.2 194.24, d 0.76) Patien 35 35 0.90 38 1.0 .5 .7 .44 1.65 18.04, df 0.70) Severe g n 5 7.7 0.6 7.7 0.6 7.7 0.6 8.5 2.5	$\begin{array}{c} 73\\ \text{f}=7\ (\text{P}\\ \\ \begin{array}{c} \text{sb}\\ \text{SD}\\ \text{Tot}\\ \\ \text{SD}\\ \text{Tot}\\ \\ \text{SD}\\ \\ \begin{array}{c} \text{Tot}\\ \text{SD}\\ \\ \text{SD}\\ \\ \begin{array}{c} \text{Tot}\\ \text{SD}\\ \\ \\ \begin{array}{c} \text{SD}\\ \text{Tot}\\ \\ \\ \begin{array}{c} \text{SD}\\ \text{SD}\\ \\ \end{array} \end{array}$	9 tal Me 44 8.1 40 8 24 7 717 10.1 65 = 0.001); al Mee 1 8.5 3 7.5 9 8.9 4 9.9	Mild SI 1/2 - 2 - 3 0.6 .9 0.1 .9 0.6 .8 1. .8 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 2.3 .9 2.3 .9 2.3	363 996% → Total 2 40 3 25 2 24 7 24 193 40 78 93 40 78 16 122	100.0% Weight 21.7% 16.2% 23.1% 21.0% 100.0% Weight 20.9% 19.4% 20.6% 18.0% 21.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54 -1.39 [-1.89, -0.88] -0.17 [-0.55, 0.22] 0.11 [-0.53, 0.74] 0.24 [-0.10, 058]	Year 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Erbis, 2015 (vs controls) Erbis, 2015 (vs controls) Osada, 2012 (vs controls) Osada, 2012 (vs controls)	9.5 ; Chi ² = - 0.31 (P = 	3 1.2 194.24, c 0.76) Patien 35 35 0.90 38 1.00 .5 1.00 .6 1.00 .7 0.10 18.04, df 0.70) Severe n 5 7.7 0.6 7.7 0.5 9.6 1	73 5D To 5D To 32 1 12 332 1 132 1332 1 14 4 4 5 5 5 5 1 6 1 1 1 1 1 1 1 1	9 tal Me 44 8.1 40 8 24 7 717 10.1 65 = 0.001); al Mee 1 8.5 3 7.5 9 8.9 4 9.9	Mild SI 1/2 - 2 - 3 0.6 .9 0.1 .9 0.6 .8 1. .8 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 1. .9 2.3 .9 2.3 .9 2.3	363 96% 15 2 40 3 25 2 40 3 25 4 70 3 25 4 70 3 25 5 24 1 93 3 40 5 24 1 93 5 40 1 93 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	100.0% Weight 21.7% 18.1% 16.2% 23.1% 21.0% 100.0% Weight 20.9% 19.4% 20.6% 18.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54 -1.39 [-1.89, -0.88 -0.17 [-0.55, 0.22 0.11 [-0.53, 0.74]	Year 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI
Yarkac, 2019 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 1.05 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Akbal, 2013 (vs controls) Akbal, 2013 (vs controls) Lei, 2017 (vs controls) Total (95% CI) Heterogeneity: Tau ² = 0.14 Test for overall effect: Z = 1 Study or Subgroup Beyazit, 2012 (vs controls) Erbis, 2015 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Akbal, 2012 (vs controls) Lei, 2017 (vs controls) Lei, 2017 (vs controls) Cosada, 2012 (vs controls) Yarkac, 2019 (vs controls)	9.5 ; Chi ² = -).31 (P = 8.37(9.5 8 7 10.4 ; Chi ² = -).38 (P = Mea	3 1.2 194.24, d 0.76) Patien 35 38 1.0 .5 1.0 .7 1.4 1.65 1.4 1.65 1.4 7.7 0.6 7.7 0.6 8.04, df 0.70) Severe \$\$ 7.7 9.6 1 9.8 1.3	$\begin{array}{c} 73\\ \mathbf{f}=7\ (P\\ \mathbf{SD}\ \mathbf{Tot}\\ \mathbf{SD}\ \mathbf{SD}$	9 tal Me 44 8.1 40 8 24 7 17 10.1 65 = 0.001); al Mea 1 8.3 5 9.8 3 9.8 3 9.8 5 9.8	O1); I ² = Contrct an SI 33 0.6 .6 0.7 .8 1. .98 1. Mild SD Mild SD 33 0.7 34 0.7 35 0.8 35 0.8 36 1.2	363 996% 5 7 Total 2 40 3 40 5 2 24 1 70 4 34 193 40 78 16 122 349	100.0% Weight 21.7% 16.2% 23.1% 21.0% 100.0% Weight 20.9% 19.4% 20.6% 18.0% 21.0%	0.12 [-0.61, 0.84] Std. Mean Difference IV, Random, 95% CI -0.29 [-0.65, 0.06] 0.48 [-0.03, 0.98] 0.90 [0.30, 1.50] -0.10 [-0.39, 0.18] -0.34 [-0.72, 0.05] 0.07 [-0.31, 0.46] Std. Mean Difference IV, Random, 95% CI -0.90 [-1.25, -0.54 -1.39 [-1.89, -0.88] -0.17 [-0.55, 0.22] 0.11 [-0.53, 0.74] 0.24 [-0.10, 058]	Year 2012 2013 2014 2017	Std. Mean Difference IV, Random, 95% CI

Figure 2 Meta-analysis (A) Onset vs. Remission, (B) Onset vs. Controls, (C) Remission vs. Controls and (D) Severe vs. Mild cases of acute pancreatitis (AP) at onset CI, confidence interval; SD, standard deviation

Table 2 Meta-regression analysis

Parameter	Univariate analysis (r)	Univariate P-value	Meta-regression analysis (standardized beta)	Meta-regression P-value
Study characteristics				
Sample size	-0.014	0.969		
Years passed from publication	0.162	0.655		
Cohort study	-0.161	0.656		
Including severe cases	-0.068	0.852		
Adjustment for confounders				
Age	-0.592	0.036	-0.277	0.336
Sex	-0.684	0.015	-0.304	0.322




Figure 3 Funnel plot with trim-and-fill analysis *CES, combined effect size*

Table 3 Subgroup analysi	VS1S	
--------------------------	------	--

Parameter	Subgroups	SMD	95%CI	I^2	P-value
Age adjustment	Yes	-0.21	-0.40 to -0.03	58%	< 0.001
	No	-0.80	-1.07 to -0.54	0%	
Sex adjustment	Yes	-0.52	-0.77 to -0.27	60%	0.01
	No	-0.07	-0.32 to 0.19	60%	

SMD, standardized mean difference; CI, confidence interval

attributing the observed difference to early-onset infection in non-biliary AP patients [18]. However, Yarkaç *et al* failed to reproduce this finding [20].

Lei *at al* studied the time course of MPV alterations in AP by measuring it at admission (day 1), and on days 2, 3 and 7. The authors reported a lower MPV in AP patients at admission compared to days 2, 3 and 7, while they suggested that an MPV less than 6.65 fL at admission for AP could predict organ failure [19]. However, whether MPV could possibly serve as a predictor of the severity of AP as well as of complications of the disease needs further, carefully designed clinical studies.

Our meta-analysis incorporated all the above mentioned data, simultaneously performing quality assessment, publication bias analysis, subgroup analyses and metaregressions. Although NOS cannot discriminate between studies of "high" and "low" quality, it constitutes a valuable tool for forming inclusion criteria for the meta-analysis, informing a sensitivity analysis or meta-regression, weighting studies, or highlighting areas of methodological quality poorly addressed by the included studies [21]. Subgroup analyses and meta-regressions focused on the potential effect of study type, sample size, region of origin, confounders, and combined outcomes.

Interestingly, no publication bias was detected, as implied by results derived from Eggers' regression, funnel plot with trim-and-fill analysis, standardized residual histogram, Galbraith plot, normal quintile plot, Rosenthal failsafe-N test, Orwin failsafe-N test and Gleser & Olkin number of unpublished studies; this result could be attributed to the fact that no clear-cut predefined or prejudged size or even direction of difference was suspected in the scientific community as a whole.

No statistically significant model analyzing study characteristics and confounders explained the observed increased heterogeneity (I^2 =72%, P≤0.001) by meta-regression. However, subgroup analysis revealed age (P<0.001) and sex (P=0.010) adjustment as potential sources of heterogeneity. These findings are in keeping with the current knowledge and literature, as age and sex are known determinants for AP; the incidence of AP increases with age and it is twice more common in males than females worldwide [22]. All the above underlie the need for careful interpretation of data already published, as well as study design and performance in the future.

Summing up, the present meta-analysis suggested that MPV is higher at remission of AP than at the onset of the disease, and subgroup analysis indicated comparable MPV in relation to AP severity. However, no statistically significant difference was detected between AP patients and controls at either onset or remission of the disease. These findings are in keeping with initial platelet activation and wear, resulting in lower MPV, and subsequent reactive thrombocythemia leading to an increase of large platelets during inflammation [23].

The inconsistencies that the above-mentioned findings may seem to convey could at first be attributed to the fact that the data were derived from different studies for each comparison, as well as to the substantial heterogeneity. Seemingly, mean MPV values, despite being lower at the onset of AP than at remission of the disease, could be supposed to lie within the normal range in both cases.

The major limitation of the present study might be that the data analyzed were derived from case-control studies. Interestingly though, meta-regression did not prove any statistically significant difference regarding overall effect sizes; however, due to the fact the pooled studies were observational, residual confounding is a major limitation and even the meta-regression cannot control unknown confounders. Thus, this practice might be considered nondecisive. Furthermore, the present study failed to incorporate unpublished data; lack of this kind of source might be linked to potential publication bias, despite the fact that no prejudiced correlation between MPV and AP (positive or negative) prevailed in the literature. Such biases might not be traced in small-sized studies including less than 10 studies due to the fact that funnel plots, as well as any statistical tool used for the same purpose, are underpowered.

In conclusion, our results suggest that MPV is lower at the onset of AP than at remission of the disease, independently of the disease severity. As MPV constitutes an inexpensive and undemanding marker, it would be reasonable to further investigate its potential prognostic value. Therefore, further specially designed clinical evaluations would be needed to assess the clinical usefulness of MPV in everyday clinical practice.

Summary Box

What is already known:

- A higher activated platelet ratio has been observed at the onset of acute pancreatitis (AP)
- Greater platelet adhesiveness and aggregation has been documented in the early stages of AP
- Studies have reported statistically significant differences in mean platelet volume (MPV) between the onset and remission of AP

What the new findings are:

- MPV is smaller at the onset of AP
- MPV is independent of the severity of AP
- MPV, an inexpensive and undemanding marker, deserve further investigation of its potential prognostic value in AP


References

- Kakafika A, Papadopoulos V, Mimidis K, Mikhailidis DP. Coagulation, platelets, and acute pancreatitis. *Pancreas* 2007;**34**:15-20.
- 2. Mimidis K, Papadopoulos V, Kotsianidis J, et al. Alterations of platelet function, number and indexes during acute pancreatitis. *Pancreatology* 2004;4:22-27.
- Mimidis K, Papadopoulos V, Kartasis Z, et al. Assessment of platelet adhesiveness and aggregation in mild acute pancreatitis using the PFA-100 system. JOP 2004;5:132-137.
- Huang P, Zhang Y, Wu H. Mean platelet volume as an indicator of persistent organ failure in acute pancreatitis. *Int J Clin Exp Pathol* 2016;9:12883-12889.
- 5. Moher D, Shamseer L, Clarke M, et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- Shea BJ, Reeves BC, Wells G et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
- 7. Stang A. Critical evaluation of the Newcastle-Ottawa scale for

the assessment of the quality of nonrandomized studies in metaanalyses. *Eur J Epidemiol* 2010;**25**:603-605.

- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
- 9. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014;**14**:135.
- Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of meta-essentials: a free and simple tool for metaanalysis. *Res Synth Methods* 2017;8:537-553.
- 11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-560.
- Yilmaz N, Ozkan OV, Buyukbas S, et al. Mean platelet volume in patients with acute pancreatitis. J Clin Exp Invest 2011;2:362-365.
- 13. Beyazit Y, Sayilir A, Torun S, et al. Mean platelet volume as an indicator of disease severity in patients with acute pancreatitis. *Clin Res Hepatol Gastroenterol* 2012;**36**:162-168.
- Osada J, Wereszczynska-Siemiatkowska U, Dabrowski A, Dabrowska MI. Platelet activation in acute pancreatitis. *Pancreas* 2012;**41**:1319-1324.
- Akbal E, Demirci S, Koçak E, Köklü S, Başar O, Tuna Y. Alterations of platelet function and coagulation parameters during acute pancreatitis. *Blood Coagul Fibrinolysis* 2013;24:243-246.
- Kefeli A, Basyigit S, Özgür Yeniova A, Küçükazman M, Nazligül Y, Aktas B. Platelet number and indexes during acute pancreatitis. *Euroasian J Hepatogastroenterol* 2014;4:67-69.
- Erbis H, Aliosmanoglu I, Turkoglu MA, Ay E, Turkoglu A, Ulger BV. Evaluating mean platelet volume as a new indicator for confirming the diagnosis of necrotizing pancreatitis. *Ann Ital Chir* 2015;86:132-136.
- Okuturlar Y, Soylu A, Dogan H, et al. Mean platelet volume in patients with biliary and non-biliary acute pancreatitis. *Int J Clin Exp Pathol* 2015;8:2051-2056.
- Lei JJ, Zhou L, Liu Q, Xiong C, Xu CF. Can mean platelet volume play a role in evaluating the severity of acute pancreatitis? *World J Gastroenterol* 2017;23:2404-2413.
- Yarkaç A, Köse A, Bozkurt Babuş S, Ateş F, Örekici Temel G, Ölmez A. The value of hematological parameters in acute pancreatitis. *Ulus Travma Acil Cerrahi Derg* 2019;25:453-460.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. *Eur J Epidemiol* 2010;25:603-605.
- Petrov MS, Yadav D. Global epidemiology and holistic prevention of pancreatitis. *Nat Rev Gastroenterol Hepatol* 2019;16:175-184.
- Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. *Mediators Inflamm* 2019;2019:9213074.

Supplementary material



Supplementary Figure 1 Galbraith plot